Beam one-ups Wave as both show promise of genetic editing for AATD

Beam Therapeutics' Gene Editor Shows Strong Efficacy in AATD Trial

Beam Therapeutics and Wave Life Sciences recently presented encouraging Phase 1/2 and Phase 1b/2a data, respectively, for their genetic editing therapies targeting alpha-1 antitrypsin deficiency (AATD). Beam's DNA editor, BEAM-302, demonstrated an approximately 80% reduction in circulating mutated AAT protein and increased healthy AAT levels above the protective threshold of 11 μM, with effects persisting for 12 months. Wave's subcutaneous RNA editor, WVE-006, showed up to a 59.1% reduction in mutated AAT with a single dose, improving to 70.5% with multiple doses. Analysts suggest Beam holds an efficacy advantage and is positioned for a first-mover advantage in pivotal enrollment and launch, with both companies pursuing accelerated approval pathways.

• Beam Therapeutics' BEAM-302, a DNA editor, showcased strong Phase 1/2 results for AATD. A single dose of 60-mg or greater led to an approximately 80% reduction in mutated alpha-1 antitrypsin (AAT) protein levels. Crucially, it also raised healthy AAT levels above the protective threshold of 11 μM, with these biomarker dynamics proving robust and persisting through 12 months of follow-up, indicating a durable genetic correction.
• Wave Life Sciences presented Phase 1b/2a data for its subcutaneous RNA editor, WVE-006. This investigational oligonucleotide therapy demonstrated a significant reduction in the mutated and toxic form of AAT, achieving up to 59.1% with a single dose and increasing to 70.5% with multiple doses. The treatment also restored the expression of wild-type AAT, highlighting its potential to correct the underlying genetic defect at the RNA level.
• Analysts have positioned Beam Therapeutics with an efficacy advantage over Wave Life Sciences, noting that WVE-006 might be reaching an efficacy "ceiling" even with multiple doses. Both companies are pursuing accelerated approval pathways with the FDA. Beam plans to launch a pivotal cohort for BEAM-302 in the latter half of 2026, while Wave expects regulatory feedback for WVE-006 by mid-2026, setting the stage for a competitive race to market.

Addressing Unmet Needs in Alpha-1 Antitrypsin Deficiency

Recent literature highlights significant gaps in alpha-1 antitrypsin deficiency (AATD) management that persist despite advancing therapeutic options. The field continues to grapple with fundamental challenges around diagnosis, treatment optimization, and understanding disease heterogeneity. Multiple underserved populations have emerged as priority targets for improved care delivery.

• Severely underdiagnosed patient populations - Only 4.6% of guideline-concordant cases receive appropriate testing even after implementing electronic medical record prompts, with 25% of European physicians unaware of local AATD testing guidelines and delayed diagnosis associated with patient harm

• Patients with non-traditional disease phenotypes - The clinical spectrum now extends beyond the traditional younger emphysematous patient paradigm to include associations with asthma, bronchiectasis, and other chronic respiratory conditions requiring deeper evaluation of clinical, radiological, and functional variables

• Heterozygous carriers (PI*MZ genotype) - This population faces unclear lung disease risk and variable AAT levels that complicate prognosis, though prognostic models show effectiveness in detecting early emphysema progression among smokers with mild to moderate deficiency

• Patients requiring dual organ system treatment - Limited therapeutic options exist for liver disease manifestations, with current augmentation therapy primarily targeting pulmonary disease while novel approaches like dual SORT LNPs aim to deliver treatments to both liver and lung tissues

• Individuals needing personalized risk stratification - DLCO, BODE, and BODEx emerge as independent predictors of exacerbations, with Pi*ZZ phenotype patients three times more likely to experience exacerbations compared to other genotypes, supporting development of individualized therapeutic regimens

• Populations with uncertain augmentation therapy outcomes - Questions remain regarding optimal dosing, administration routes, and effects on exacerbation frequency, quality of life, lung function decline, and mortality, particularly given the expensive and variably accessible nature of current treatments

BEAM-302's Promising Phase 1/2 Data for AATD

The ATALANTa and ASTRAEUS studies represent landmark Phase 2 trials evaluating alvelestat, an oral neutrophil elastase inhibitor, in alpha-1 antitrypsin deficiency. These complementary, double-blind, randomized, placebo-controlled trials enrolled 161 participants across 12 weeks, with ATALANTa investigating 120 mg twice daily (including participants receiving augmentation therapy) and ASTRAEUS testing both 120 mg and 240 mg twice daily without augmentation. The primary endpoints focused on changes in blood neutrophil elastase and its activity markers, specifically Aα-Val and desmosine/isodesmosine levels.

Efficacy results demonstrated dose-dependent neutrophil elastase suppression, with the 240 mg twice daily regimen achieving over 90% suppression of blood neutrophil elastase. Critically, only the higher dose demonstrated clinically relevant effects on disease activity biomarkers, showing significant reductions in Aα-Val and desmosine compared to placebo, while the 120 mg dose showed no impact on these markers. The safety profile proved favorable across both doses, with headache emerging as the most common adverse event, particularly at the 240 mg dose, though no concerning safety signals were identified.

A multicenter retrospective study examined augmentation therapy in 27 patients with intermediate AATD (serum AAT 50-110 mg/dL) and COPD/emphysema over 12 months. Despite current guidelines not recommending augmentation for this population, the study revealed significant clinical benefits including reduction in annual exacerbations from a median of 2 to 1 (p < 0.0001) and meaningful improvement in St. George's Respiratory Questionnaire scores exceeding the minimal clinically important difference for COPD. However, no significant changes were observed in spirometry or diffusion capacity, and the authors emphasized these hypothesis-generating findings require prospective validation given the retrospective design and small sample size.

Comparing Emerging DNA and RNA Editing for AATD

The treatment landscape for alpha-1 antitrypsin deficiency has demonstrated both continuity and emerging innovation over the past five years, with intravenous augmentation therapy remaining the cornerstone of disease-modifying treatment while new therapeutic approaches enter development. Augmentation therapy, which has remained essentially unchanged for over 35 years, continues to require weekly or biweekly intravenous administration for life and remains expensive with variable global availability. Notably, this treatment remains unavailable to patients in the United Kingdom as of 2023, highlighting persistent access challenges in the therapeutic landscape.

Recent clinical evidence has provided more nuanced insights into augmentation therapy's efficacy profile and clinical outcomes. Studies from 2023-2024 revealed that patients receiving augmentation therapy showed 1.43 fewer points per year deterioration in St George's Respiratory Questionnaire scores compared to controls, though mortality benefits remained less definitive with median 7-year survival rates of 87.8% versus 82.7% in controls. The therapy demonstrates clear biochemical efficacy by raising AAT levels in serum and lung epithelial lining fluid, reducing inflammatory mediators, and radiologically slowing lung density loss. However, effects on exacerbation frequency, quality of life, lung function decline, and mortality remain less conclusively established, partly due to the challenges of conducting adequately powered randomized trials in this rare disease population.

The evolving landscape also reveals significant variability in clinical practice and emerging therapeutic horizons. A 2022 European expert survey demonstrated substantial inconsistency in prescription criteria, with agreement among experts in only 58.2% of cases, though factors such as AAT genotype, serum levels, and FEV1 decline consistently influenced treatment decisions. Simultaneously, the therapeutic pipeline is expanding with inhaled AAT formulations, recombinant fusion proteins, RNA-editing platforms, and CRISPR-based DNA editing strategies in development. These emerging approaches aim to address current limitations of intravenous administration and potentially restore endogenous AAT production, representing the most significant potential advancement in the treatment paradigm since augmentation therapy's introduction.

Next Steps for AATD Genetic Editing Therapies

Several key trials have evaluated alpha-1 antitrypsin deficiency (AATD) treatments using diverse study designs and endpoints. The most comprehensive evidence comes from randomized controlled trials analyzing augmentation therapy, complemented by observational studies and specialized intervention trials.

Genetic Editing Nears a New Frontier in AATD Treatment

The recent data from Beam Therapeutics and Wave Life Sciences heralds a potentially transformative era for patients with alpha-1 antitrypsin deficiency (AATD). For years, treatment options for this inherited disorder have been limited, but the emergence of genetic editing therapies offers the promise of addressing the root cause of the disease. Beam's BEAM-302, a DNA editor, has demonstrated remarkable efficacy, not only significantly reducing the mutated AAT protein but also elevating healthy AAT levels above the critical protective threshold of 11 μM, with effects persisting for a year. This is a crucial clinical milestone, suggesting the potential for a profound impact on disease progression.

Wave Life Sciences' WVE-006, an RNA editor, also showed promising reductions in mutated AAT, further validating the power of genetic editing. The competitive dynamic between these two companies is intense, with analysts noting Beam's potential efficacy advantage and a strong position for first-mover status. However, Wave's subcutaneous delivery method presents a compelling convenience factor that could differentiate it in the market, even as both companies race towards accelerated approval. The broader implications extend beyond AATD; Beam Therapeutics' involvement in base editing for other genetic disorders, such as sickle cell disease with risto-cel, underscores the versatility and clinical progress of their platform technology. This suggests that successful translation in AATD could de-risk and accelerate development for a host of other genetic conditions.

However, the path forward is not without its considerations. While the initial data is encouraging, the long-term durability and safety of these novel genetic editing therapies remain paramount. The experience with other genetic therapies, including Beam's own risto-cel, indicates that adverse events, some severe, can occur. Furthermore, the specific requirements for accelerated approval and subsequent confirmatory trials will be critical for market access and sustained commercial success. Ultimately, these developments represent a significant leap forward, offering genuine hope for patients and validating genetic editing as a powerful new frontier in medicine.